CAS: 63096-02-6; Boc-Leu-Ome

相似化合物

133467-01-3 5845-53-4 7517-19-3

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号7517-19-3 L-亮氨酸甲酯盐酸盐 | CAS号2666-93-5 methyl L-leucinate | CAS号67-56-1 甲醇 | CAS号13139-15-6 B°C-L-亮氨酸 | CAS号1115-39-5 N-Trifluoroacet... | CAS号74-88-4 碘甲烷 | CAS号61-90-5 L-亮氨酸 | CAS号58632-95-4 2-(叔-丁氧基碳酰胺)-2-苯乙腈 | CAS号82010-31-9 N-B°C-L-亮氨醇 | CAS号70533-96-9 b°C-l-亮氨酰胺 | CAS号58521-49-6 (3S,4S)-4-((叔丁氧... | CAS号13139-15-6 B°C-L-亮氨酸 | CAS号118283-03-7 (R)-1-(苄基氨基)-4-... | CAS号51021-87-5 CBZ-亮氨酸甲酯

📜L-亮氨酸置于乙酰氯体系中,用 四氢呋喃,甲醇 作为反应溶剂,化学反应 36.0H,反应生成 Boc-L-亮氨酸甲酯
参考文献:具有ucp拓扑结构的新的等规,同手性金属有机框架
标题:具有ucp拓扑结构的新的等规,同手性金属有机框架
摘要:基于铜桨轮基序和一组新的同手性连接基,已经合成了一个新的等网状金属-有机骨架系列,称为uhm-25(uhm:汉堡材料大学).从手性库中可用的氨基酸开始,建立了合成程序,该程序允许在4-5个步骤中直接,数克规模的同手性连接体合成.这些接头带有已被证明可用于立体选择性有机化学的取代基,例如伊文思助剂或手性氨基醇.所得的mof仅在氨基酸原料提供的手性部分上有所不同.uhm-25的结构由cu 2的立方八面体笼组成通过连接子的间苯二甲酸酯部分连接的桨轮图案.这些笼通过连接子的弯曲骨架连接在一起,从而形成原始的立方排列,从而产生了稀有的下层(3,4)-C双齿净ucp.uhm-25系列的mof的表面积高达s Bet = 1900 M 2 / G.具有非常好转化率的合成后修饰反应证实了手性基团的可及性.此外,带有丙醇功能的uhm-25-Pro被用于乙醛的自定向对映选择性醇醛加成中,证明了uhm-25系列在多相,立体选择性催化方面的潜力.
DOI:10.1021/acs.Chemmater.5B03723

专利信息

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-7642369-B2
优先权日:2006-09-12
标 题 :Epoxyketone-based immunoproteasome inhibitors
发明人：KIM KYUNG BO; HO YIK KHUAN
权利人:UNIV KENTUCKY RES FOUND
摘要:An efficient new route for the preparation of dihydroeponemycin, an active eponemycin derivative, is provided, which includes the synthesis of the intermediate compound, a hydroxymethyl-substituted enone. In addition, a method is provided for synthesizing inhibitors, which includes PI′-modified analogues. These analogues selectively bind to a major immunoproteasome catalytic subunit LMP2 and inactivate its proteolytic activity in a method of treating diseases, including myeloma and other cancers, Huntington's disease and Alzheimer's disease.

专利号:US-4609643-A
优先权日:1980-08-06
标 题:Renin inhibitors, treatments and dipeptide synthesis
发明人：SZELKE MICHAEL; JONES DAVID M; HALLETT ALLAN
权利人:HAESSLE AB
摘要:Preparation of renin inhibitors based on the structure of natural renin substrate at residues 6 to 13 from the amino terminal thereof, the inhibitors being polypeptide analogues having in particular an isosteric non-peptide link corresponding to the 10, 11 peptide link of the substrate, and preparation of dipeptide analogues.

专利号:US-8129411-B2
优先权日:2005-12-30
标题:Organic compounds
发明人：EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI
权利人:EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. n The compounds have the formula I′ n nwherein R1, R2, T, R3 and R4 are as defined in the specification.